ASBPW · Aspire Biopharma Holdings, Inc.

Aspire Biopharma Holdings, Inc., a biopharmaceutical company focused on sublingual drug delivery technology, announced a Letter of Intent to acquire Dura Driver Control Systems (DCS), a tier-one automotive supplier specializing in vehicle electrification, safety, and human-machine interface systems. This proposed $30 million all-cash transaction for 100% of DCS marks a transformative pivot for Aspire into the high-revenue automotive sector, diversifying from its core biopharma operations into a business with established scale and profitability. DCS generated over $200 million in revenue and more than $22 million in Adjusted EBITDA for its fiscal year ended December 31, 2025 (unaudited), alongside net income exceeding $17 million, underscoring its financial strength and free cash flow generation. The target's competitive moat includes over 310 patents covering 275 parts for 150+ vehicle platforms across major OEMs, supported by 55 engineers in two global technical centers and 11 manufacturing facilities in North America, Europe, and Asia. Long-term customer relationships average 28 years with top 10 clients supporting 250 high-volume models. Post-acquisition, DCS management will be enhanced by a Lakewood & Company team bringing over 200 years of collective automotive expertise. Completion hinges on due diligence, a U.S. GAAP audit, and a definitive agreement, with no assurances of closing on current terms or timeline. RBW Capital Partners LLC serves as exclusive financial advisor. This acquisition could position Aspire as a diversified enterprise but carries integration risks, automotive cyclicality, and customer concentration dependencies as noted in forward-looking disclosures.